Literature DB >> 7846113

Vascular targeting--a new approach to the therapy of solid tumors.

F J Burrows1, P E Thorpe.   

Abstract

An attractive approach to the therapy of solid tumors is to attack the endothelial cells of the tumor vascular bed rather than the tumor cells themselves, which circumvents the problem of poor penetration of tumor masses by monoclonal antibodies and other macromolecules. In this review, we will discuss the drawbacks of targeting solid tumors and the advantages of the 'vascular targeting' approach, describe the validation of the concept in a mouse model and summarize the properties of tumor endothelial cell markers, which are candidates for vascular targeting in humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846113     DOI: 10.1016/0163-7258(94)90037-x

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  20 in total

1.  Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery.

Authors:  Deirdre P McIntosh; Xiang-Yang Tan; Phil Oh; Jan E Schnitzer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 2.  Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems.

Authors:  Daniel J Sobczynski; Margaret B Fish; Catherine A Fromen; Mariana Carasco-Teja; Rhima M Coleman; Omolola Eniola-Adefeso
Journal:  Ther Deliv       Date:  2015-08-14

3.  Screening phage display libraries for organ-specific vascular immunotargeting in vivo.

Authors:  Philippe Valadon; Jeff D Garnett; Jacqueline E Testa; Marc Bauerle; Phil Oh; Jan E Schnitzer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-29       Impact factor: 11.205

4.  Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung.

Authors:  Phil Oh; Per Borgström; Halina Witkiewicz; Yan Li; Bengt J Borgström; Adrian Chrastina; Koji Iwata; Kurt R Zinn; Richard Baldwin; Jacqueline E Testa; Jan E Schnitzer
Journal:  Nat Biotechnol       Date:  2007-03-04       Impact factor: 54.908

Review 5.  Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Authors:  Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

Review 6.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 7.  Antiangiogenesis as a novel therapeutic concept in pediatric oncology.

Authors:  L Schweigerer
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

Review 8.  Combined interventional therapies of hepatocellular carcinoma.

Authors:  Jun Qian; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes.

Authors:  Alessandro Ruggiero; Carlos H Villa; Jason P Holland; Shanna R Sprinkle; Chad May; Jason S Lewis; David A Scheinberg; Michael R McDevitt
Journal:  Int J Nanomedicine       Date:  2010-10-05

10.  Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.

Authors:  Kyeongsoon Park; Yoo-Shin Kim; Gee Young Lee; Rang-Woon Park; In-San Kim; Sang Yoon Kim; Youngro Byun
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.